Recent Updates
Recently added Catalysts

Propafenone

Phase 1

Arrhythmia, Cardiac | Small molecule | Cardiovascular |GSK plc|Last Updated: Jun 12, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment38
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01956487Bioequivalence of RYTHMOL SR® Manufactured at Two Different SitesPHASE1 COMPLETED 38Apr 11, 2012Jun 27, 2012Jun 12, 20171 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Bioequvalence
48 hours

Two formulations of propafenone hydrochloride

Secondary Endpoints
Pharmacokinetics
48 hours
Adverse events
48 hours
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeOTHER
Treatment Arms
ArmTypeDescription
PropafenoneOTHEROpen label comparison of 2 formulations
Interventions
NameTypeDescription
PropafenoneDRUGComparison of drug from 2 manufacturing sites
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Male or female between 18 and 55 years of age inclusive, at the time of signing the informed consent. * Body weight greater than or equal to 50kg and BMI within the range 18.5 - 31.0kg/m2 (inclusive). * Healthy as determined by a responsible and experienced physician, based on...

Countries:United States
Unlock Eligibility Criteria